A Publication Describing the First Treatment of Ebola with the Aethlon Hemopurifier®
Posted on Thursday, February 12th, 2015 at 2:36 pm
47 2 36 Google +2
In my last article published on “The Chairman’s Blog,” I discussed factors underlying the increased incidence of viral epidemics, disclosed that we launched our first FDA approved clinical study and shared mechanistic details underlying our vision for treating infectious viral pathogens. Instead of deploying a drug mechanism to inhibit the replication of a single viral species, I referenced that we created the Aethlon Hemopurifier® to capture broad-spectrum circulating viruses (including many viruses not treatable with antiviral drugs) through lectin affinity attachment to a unique structure that viruses co-opt from host cells during replication. To be more specific, this unique structure resides on glycoproteins that coat the surface of infectious viruses. In well studied viruses such as HIV, it is clearly understood that virally shed glycoproteins play a role in immune suppression (the hallmark of AIDS) and perform other deleterious mechanisms to enable continued progeny virus replication. Beyond the broad-spectrum clearance of infectious viruses, an under-appreciated mechanism of Hemopurifier® therapy is its ability to capture glycoproteins once they shed from the surface of the virus.
Yesterday, the journal “Blood Purification” published a manuscript describing the first administration of Hemopurifier® therapy to an Ebola patient. The publication is entitled, “Extracorporeal Virus Elimination for the Treatment of Severe Ebola Virus Disease – First Experience with Lectin Affinity Plasmapheresis.” The lead author of the publication administered Hemopurifier® therapy to an infected patient at Frankfurt University Hospital in Germany. The publication reports that 253 million copies of Ebola virus were captured within the Hemopurifier® during a single 6.5 hour treatment. Additionally, based on pre and post treatment measurements, a 63-fold reduction in viral load was observed. The paper also discusses the mechanism of the Hemopurifier® to eliminate Ebola glycoproteins, which the authors identify as decoys that neutralize antibody response and trigger lymphocyte apoptosis. The authors also report that shed glycoproteins induce a massive release of cytokines and increase vascular permeability, which in turn leads to: systemic inflammation, electrolyte disturbances, septic shock-like syndrome, multi-organ failure, and death. The article can be accessed online at: http://www.karger.com/Article/Abstract/375229
I look forward to keeping you updated on the progress of our Hemopurifier® therapy and thank you for taking the time to read this blog.
Leave a Reply
You must be logged in to post a comment.
hooseerfan
February 12, 2015 - 7:29 pm
Please Mr Joyce respond to your shareholders cries for more communication. We all believe in the HP but where are we going from here after our success in helping treat DR Mawanda but he has been the one and only patient? How can you not see the stress the rapid rise and fall of the stock has been on the long term shareholders. The lack of communication including no reassurances that the data presented was accurate and of great importance in the recovery of Dr Mawanda even after the attacks from outside financial bloggers, We have received no explanation of why it was necessary to go to predatory financiers in order to obtain funding for the trials which has literally taken millions away from the market and shareholder value.
Log in to Reply
James Joyce
James Joyce
February 13, 2015 - 10:54 am
I appreciate your comment and recognize and value you as a long-term shareholder. I hope you enjoyed the first scientific journal account depicting the successful deployment of our Hemopurifier® to treat a comatose ebola patient with multiple organ failure. In regards to communications, you may have noted (as reflected in our SEC filings) that on December 30th we filed an S-1 registration statement that was subsequently deemed effective by the SEC at the end of January. During the period this registration statement was pending with the SEC, our communications were constrained. In regards to our most recent financing, it placed a $90 million+ valuation on our company based on a straight equity structure. It was the highest financing valuation in the history of our organization and was priced approximately 100% higher than a transaction completed the previous month. We closed the financing with a single institutional healthcare investor and it was managed by Roth Capital, a well established small-cap investment banking firm that has raised more than $10.6 billion for its clients. Beyond reducing balance sheet risk, the transaction provided resources to conduct our FDA approved study, which represents the foundation of a multi-indication U.S. clinical progression model to optimize long-term shareholder value. It also allowed us to clean up certain past due debts as reflected in the 10-Q we filed with the SEC earlier this week. As reported in the 10-Q, debt reduction and equity financings contributed to a $16 million positive shift in shareholder equity since our 3/31/14 fiscal year end.
Log in to Reply
hooseerfan
February 16, 2015 - 2:23 pm
Sorry Mr Joyce, I have not been back to see your reply but thankfully a poster on Investors Village posted it and I saw it there
Thank you for your reply and some clarification of the financing. I understand there was a “quiet period” the SEC required to submit to and hope we will now get back on track including your communications with shareholders.
I am sure you have your hands full and are very busy but I hope you can see this from a shareholders perspective especially many of us who have been with you a long time. We have all bought our stock on the open market at retail prices and have watched the share mostly erode over time but the success with Ebola gave us renewed hope we may start seeing some of the upward pricing we have all hoped for.
I am not sure where we are going to fit in with HCV since the new highly effective treatments have been getting approved and coming to the marketplace. These drugs are safe and effective, can be used in liver compromised patients with efficacy over 95% and greatly reduced treatment duration. While I am sure as time goes forward the high prices will have pressure to be drastically reduced with some exclusive contracts already happening so where is our niche going to be in all of this? What happened with India and the sale of the HP, I haven’t seen any revenue listed from those sales? What is happening on the DARPA front are we still on track. I have heard through other posters that Battelle is actually reviewing a different company and their filter, is this true?
We need revenue even with all the great things we have seen or been made aware of as this company goes forward we need real revenues and not continued dilution. I am also going to be direct, I hope you don’t mind. With my experience and knowledge I oppose a reverse split and have not had one good experience with companies I have owned who did this. Not one of them have ever been and all I ended up with was less share count, higher cost basis and lower share price because they all immediately dropped and never recovered.
I will close for now, take care Mr Joyce and remember ‘Remember when your Shareholders are Happy the whole Company is Happy’ that includes You.
Sincerely,
Saleem and Eleanora Nasser
- See more at: http://www.thechairmansblog.com/aethlon-medical/james-joyce/publication-describing-first-treatment-ebola-aethlon-hemopurifier/#AEMD
News 
Market Data 
Discover 
